Tratamiento con células madre para la esclerosis múltiple (EM).
Los resultados provisionales de un ensayo internacional de un tratamiento de trasplante de células madre mostraron una tasa de éxito mucho mayor que la del grupo de control., que recibió un tratamiento farmacológico. La EM es una enfermedad que afecta al cerebro., médula espinal, y sistema inmunológico, leading to a number of disabilities. El tratamiento con células madre uses chemotherapy to wipe out a patient’s immune system and then “re-boots” it using stem cells from the patient’s blood and bone marrow that are unaffected by the disease.
Just over 100 people participated in the study in four cities: en Chicago, Sao Paolo, Sheffield (U.K.), and Uppsala in Sweden. They all had relapsing remitting MS, where periods of symptomatic “relapses” alternate with periods of remission. A year after the treatment, only one patient who received the tratamiento con células madre had relapsed, compared to 39 people in the control group.
In a follow-up an average of three years after treatment, el Células madre had failed in 6% (3 de 52) of recipients while the drug treatment had failed in 60% (30 de 50). The results were released at the annual meeting of the European Society for Bone and Marrow Transplantation in Lisbon.
A neurologist at Royal Hallamshire Hospital in the U.K. told the BBC this was the best result he had seen “in any trial for multiple sclerosis,” though he included the caveat that the results were only preliminary.
This study is the largest of its kind, and it bolsters results from smaller trials that have also showed stem cell transplant to be effective.
WhatsApp: +447778936902 , +33745637397, +34670491885
correo electrónico: head_office@nbscience.com